Back to Agenda
Collaboration in R&D: What’s New for TransCelerate BioPharma?
Session Chair(s)
Susan A Cantrell, RPH
Chief Executive Officer, Academy of Managed Care Pharmacy (AMCP), United States
This forum will provide highlights and accomplishments from the original five TransCelerate initiatives – development of a standardized approach for risk-based site monitoring, mutual recognition of clinical trial site qualification and training, development of clinical data standards, establishment of a comparator drug network and development of a shared investigator site portal, as well as discuss current progress of new initiatives and line extensions in 2014, including creation of common clinical trial protocol templates, development of a special populations (pediatric and minority) clinical trial network and establishment of a shared investigator registry. There will also be Q&A with the panel, which will include members of TransCelerate’s Board of Directors and Operations Committee.
Learning Objective : Discuss accomplishments to date for the TransCelerate initiatives; Describe the progress of new initiatives and line extensions in 2014.
Speaker(s)
Dalvir Gill, PHD
Chief Executive Officer, TransCelerate BioPharma Inc., United States
Panelist
John Hubbard, PHD
Chairman, Signant Health, United States
Panelist
Lynn G. Marks, MD
Senior Vice President, Projects, Clinical Platforms and Sciences, GlaxoSmithKline, United States
Panelist
Have an account?